Local view for "http://purl.org/linkedpolitics/eu/plenary/2016-04-28-Speech-2-1765-140"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20160428.134.2-1765-140"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"I supported this report, as did the majority of Members. IMI 2 was set up to finish the work carried out by IMI 1 with the aim of significantly improving the efficiency and effectiveness of the drug development process with the long-term aim that the pharmaceutical sector produces more effective and safer innovative medicines. This is a vital role, considering the difficulties many Member States are facing with access to affordable medicines. However, the funds by the joint undertaking are not utilised in a good enough manner. The rapporteur acknowledges this and calls for greater utilisation of appropriated funds. Likewise, the Court of Auditors report is based on too many general remarks, to the detriment of viable, specific ones. I am glad that the report calls for an audit with a sharper focus on the annual financial performance, on the implementation status of multi-annual projects and on the results and their implementation. Likewise, the report also rightly highlights the decrease in the overall implementation rate, which went from 99.5% in 2013 to 92.4% in 2014 for commitment appropriations and 97.5% for 2013 to 73.0% in 2014 for payment appropriations."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples